Latest 8-K filings

Addus HomeCare Corporation announced the departure of its President and Chief Operating Officer, Heather Dixon, and the interim appointment of W. Bradley Bickham to the COO role.

QXO, Inc. announced its second quarter 2026 financial results, reporting increased net sales to $3.25 billion but a net loss of $55 million, alongside adjusted diluted earnings per share of $0.08.

AmpliTech Group announced Q2 2026 results, featuring an 8.07 million revenue, up 50.9% sequentially, and a 161.2% year-over-year gross profit increase.

Swarmer, Inc. announced its second quarter 2026 financial results, showcasing revenue growth and expanded customer contracts, alongside strategic partnerships aimed at advancing drone autonomy.

Pyxus International, Inc. announced the outcomes of its 2026 annual shareholder meeting, including the election of directors and ratification of auditors.

Cibus, Inc. announced its second quarter financial results, showcasing advancements in its Rice and Sustainable Ingredients programs, favorable regulatory developments in the EU and US, and a sequential decrease in net cash usage.

Yarrow Bioscience, Inc. (now Yarrow Bioscience Operating Company Corp.) announced the completion of its merger with VYNE Therapeutics, securing approximately $200 million in financing and providing an estimated cash runway into 2028, while advancing its lead drug candidate YB-101 for autoimmune thyroid diseases.

Dillard's announced robust second-quarter results, with net income soaring to $97.7 million, driven by significant tariff rebates and a favorable litigation settlement, alongside a 1% increase in total retail sales.

Quantum-Si announced a revised Proteus launch to Q2 2027, impacting its cash runway and leading to a 20% workforce reduction.

T Stamp Inc. announced a 22% increase in net recognized revenue for H1 2026, reaching $1.66 million, and detailed strategic initiatives including participation in the EU's IPCEI program and expansion into the $48 billion Sovereign-AI market.

Assembly Biosciences reported Q2 2026 results, highlighting a $115 million financing, expansion of ABI-6250 into new indications, and progress on the GS-1179 HSV program, with cash runway projected into 2029.

Rani Therapeutics announced second quarter 2026 financial results, highlighting positive initial Phase 1a data for RT-114, a $20 million capital raise, and a new collaboration with PegBio.

Invivyd announced second quarter 2026 financial results, highlighting a 21% increase in PEMGARDA net product revenue to $14.3 million and progress in key clinical trials for VYD2311.

Merlin, Inc. announced second quarter 2026 results, highlighting advancements in autonomous flight technology and strategic partnerships, while ending the quarter with $183.9 million in cash and no debt.

Eledon Pharmaceuticals reported strong Q2 2026 results, with successful FDA meetings for its Phase 3 kidney transplant trial and promising clinical data for tegoprubart.

Ames National Corporation announced the declaration of a cash dividend of $0.24 per common share, payable September 15, 2026.

RenovoRx announced record second quarter 2026 results with 61% sequential revenue growth, raised full-year revenue guidance to $3.75M-$4.25M, and achieved full enrollment in its Phase III TIGeR-PaC trial.

MultiSensor AI Holdings, Inc. announced second quarter 2026 financial results, highlighting a 19% revenue increase to $1.7 million and an 85% surge in software revenue to $0.7 million, alongside a reduced net loss.

Eikon Therapeutics announced second quarter 2026 financial results, highlighting clinical advancements in its oncology portfolio and a robust cash reserve.

ONE Gas, Inc. has entered into an underwriting agreement for the issuance and sale of $375 million in aggregate principal amount of 5.45% Senior Notes due 2036, with proceeds intended for debt repayment and general corporate purposes.

Serina Therapeutics announced second quarter 2026 financial results, reporting progress in its SER-252 clinical trial and a strategic partnership, while also detailing operating expenses and net loss.

Singularity Future Technology Ltd. announced it has regained compliance with Nasdaq's minimum bid price requirement, averting delisting concerns.

Digimarc Corporation announced its second quarter 2026 financial results, reporting a decrease in total revenue and subscription revenue, alongside an increased net loss.

Omeros Corporation announced the appointment of Joseph Schocken to its Board of Directors, effective August 12, 2026, expanding the board to nine members.

zSpace Inc. announced second quarter 2026 financial results, reporting a net income of $0.3 million compared to a net loss of $6.1 million in the prior year, driven by substantial gross margin expansion.

Bili Social International, Inc. has filed a Form 8-K to report the termination of its Series B Preferred Stock designation, effective August 7, 2026.

Applied Materials announced record third quarter 2026 revenue of $9.12 billion, a 25% year-over-year increase, with significant growth in EPS driven by strong demand for its materials engineering solutions.

Co-Diagnostics announced its second quarter 2026 financial results, highlighting progress in manufacturing, global clinical trials, and regulatory submissions, alongside a $3.0 million private placement.

ARS Pharmaceuticals announced a strategic pivot towards targeted provider engagement for its neffy product, alongside reporting Q2 2026 financial results, including $26.2 million in U.S. neffy net product revenue.

Silexion Therapeutics Corp. announced the pricing of a public offering, raising approximately $2.5 million to advance its SIL204 clinical trial.